Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors.

A new standard for malignant pleural mesothelioma.

Hemithoracic radiotherapy for mesothelioma: lack of benefit or lack of statistical power?

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.

Localized malignant pleural mesothelioma with renal metastasis.

Trial of a 5-day dosing regimen of temozolomide in patients with relapsed small cell lung cancers with assessment of methylguanine-DNA methyltransferase.

Failure patterns after hemithoracic pleural intensity modulated radiation therapy for malignant pleural mesothelioma.

Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma.

Clinical characteristics of patients with malignant pleural mesothelioma harboring somatic BAP1 mutations.

Toxicity of initial chemotherapy in older patients with lung cancers.

Pleurectomy/decortication, chemotherapy, and intensity modulated radiation therapy for malignant pleural mesothelioma: rationale for multimodality therapy incorporating lung-sparing surgery.

New strategies in pleural mesothelioma: BAP1 and NF2 as novel targets for therapeutic development and risk assessment.

Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma.

Novel therapies in phase II and III trials for malignant pleural mesothelioma.